



Melior Is Recognized as CRO of the Year by Life Sciences Review

- > **Life Sciences Review annually selects 10 preeminent CROs and has chosen Melior Discovery as the top CRO in 2023**
- > **The editors recognized Melior’s unique capabilities in the pre-clinical *in vivo* pharmacology space with its *theraTRACE*[®] offering, its breadth of model offerings, and boutique client interaction experience**

March 19, 2024 08:00 AM Eastern Daylight Time

EXTON, Pa.--(BUSINESS WIRE)--Melior Discovery, Inc. (Melior) announced today that it has been selected as the CRO of the Year by Life Sciences Review magazine. The year-end edition of the magazine is dedicated to coverage of 10 preeminent CROs, among which Melior was selected as CRO of the Year. The recognition focused on Melior’s unique offering within the pre-clinical pharmacology space with its phenotypic screening platform *theraTRACE*[®], as well as its related offerings in the oncology space with *immuno-theraTRACE*[®], and its analgesic-focused platform *opioidTRACE*[®]. These platform offerings are in addition to Melior’s broad array of animal models of human disease.

“I am tremendously honored by this acknowledgment from the editors of Life Sciences Review,” said Andrew Reaume, Melior’s President and CEO. “This honor, together with the distinction that we received last year from Pharma Tech Outlook as a Top 20 CRO, are a testimony to the dynamic strides that Melior is making towards becoming one of the most important players in providing pre-clinical *in vivo* proof-of-concept for pharma and biopharmaceutical companies of all sorts.”

The online edition of this article can be read at: <https://www.lifesciencesreview.com/magazines/December2023/CRO/>

The magazine has provided an outlet for Melior to present its own viewpoint on the company’s philosophy towards its mission which can be read at: <https://www.lifesciencesreview.com/melior-discovery/>

About Life Sciences Review

Life Sciences Review Magazine is a print and digital magazine with a total subscription of 124,000 qualified subscribers consisting of senior decision-makers from Pharmaceutical, Biotech, Medical Device and Diagnostic space performing functions in Sales & Marketing, Manufacturing, Supply Chain, R&D, Clinical Operations, Finance, and HR. It provides a comprehensive platform for senior-level industry experts, acquirers, and decision-makers to share their insights following a unique peer learning approach.

About Melior

Melior Discovery and its sister companies, Melior Pharmaceuticals I, Inc. and Melior Pharmaceuticals II, LLC, are leaders in pharmaceutical drug repositioning using the unique *theraTRACE*[®] platform comprised of multiplexed in vivo disease models. Melior is using these capabilities to build an internal pipeline of development candidates and also partners with pharmaceutical and biopharmaceutical companies to apply the *theraTRACE*[®] platform and its in-depth in vivo pharmacology expertise to their development candidates. Melior Discovery and Melior Pharmaceuticals are privately held and located in Exton, PA. For more information, visit www.meliordiscovery.com and www.meliorpharma.com.

Contacts

Andrew Reaume, Ph.D., MBA

President and CEO

Melior Discovery, Inc.

(+1) 610-280-0633 ext 239

e-mail: areaume@meliordiscovery.com